NexGel, Inc. /
Celularity Inc.
NexGel agrees to buy Celularity's biomaterials business
Source for the buyer and target: Celularity Inc
For the buyer and target.
“On March 6, 2026, Celularity Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase and Exclusive License Agreement (the “Agreement”) with NexGel, Inc., a Delaware corporation (the “Licensee”), whereby the Company granted to the Licensee an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs as more fully described in the Agreement and the Company agreed to sell to the Licensee assets related to the portfolio (collectively, the “Business”).”
Published 10 Mar 2026
Open the sourceWhat happened
Celularity has agreed to license its commercial-stage biomaterials portfolio and certain development-stage programs to NexGel, and to sell related assets to it. The agreement was signed on March 6, 2026. [01]
Consideration can reach $35.0 million in cash, including a $15.0 million upfront payment and up to $20.0 million in milestone payments tied to net sales targets. [01]
The source
Everything on this page comes from the source below, quoted word for word.
NexGel agrees to buy Celularity's biomaterials business
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly